Media OutReach
Shenzhen and Hong Kong Join Hands to Promote the Development of the Hetao Shenzhen-Hong Kong Science & Technology Innovation Co-operation Zone
“Driving the Globalization of Clinical Trials in the Guangdong-Hong Kong-Macao Greater Bay Area, Implementing the First Key Cross-Border Multi-Center Clinical Trial Project”
HONG KONG SAR – Media OutReach Newswire – 30 July 2025 – The Greater Bay Area International Clinical Trial Institute of Hong Kong (“GBAICTI“), the Greater Bay Area International Clinical Trials Center of Shenzhen (“BAY TRIAL“), Immuno Cure BioTech (“Immuno Cure“) in Hong Kong are pleased to jointly announce today the signing of a tripartite Memorandum of Understanding (“MOU“) in Shenzhen on July 29, 2025. This collaboration aims to advance the globalization of clinical trials in the Guangdong-Hong Kong-Macau Greater Bay Area (“GBA“), further deepens clinical research cooperation between Hong Kong and Shenzhen, and implements the first ever cross-border multi-centre Phase II clinical trial project for ICVAX, a therapeutic DNA vaccine for HIV/AIDS, developed through collaboration between Immuno Cure and the AIDS Institute at the University of Hong Kong. This marks a significant milestone in the development of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Co-operation Zone.
This collaboration is witnessed by a Hong Kong Government delegation led by the Director of Health, Dr. Ronald LAM, and a Shenzhen Government delegation led by the Deputy Director General of Public Hygiene and Health Commission of Shenzhen Municipality, Ms. ZHOU Liping, following their GBA Clinical Trial Collaboration meeting held in Shenzhen.
GBAICTI and the BAY TRIAL plan to establish the GBA Clinical Trial Collaboration Platform (“Platform“) by the end of this year. The Platform is expected to offer a range of services, including project evaluation, trial design consultation, and subject recruitment planning for multi-centre clinical trials, provided by a joint Shenzhen-Hong Kong advisory team; integration of artificial intelligence technologies to assist with matching clinical trial institutions and researchers, as well as offering intelligent consultation services; establishment of a coordinated ethics review mechanism between the two regions to enhance approval efficiency; promotion of talent exchange, collaboration, and professional training; creation of a research talent pool to facilitate talent mobility and regional collaboration; and as a pilot, the development of clinical databases and biobanks based on disease areas of strength in both Shenzhen and Hong Kong.
Professor Bernard CHEUNG Man-yung, Chief Executive Officer of GBAICTI, said: “The ICVAX vaccine, developed by Immuno Cure and the AIDS Institute at the University of Hong Kong, is now poised for cross-border clinical trials in the Greater Bay Area. This highlights the achievements and potential of innovation and technology in China and the Hong Kong SAR. If the clinical trial results are positive, the new vaccine would bring hope to HIV/AIDS patients worldwide, particularly in Belt and Road countries. We aim to leverage the strength of both Guangdong and Hong Kong to establish the Guangdong-Hong Kong-Macao Greater Bay Area as a global hub for clinical trials.”
Dr. LI Yichong, Director of BAY TRIAL, said: “This collaboration marks the first cross border clinical trial project between the BAY TRIAL and Hong Kong, signifying a new phase in the cooperation between Shenzhen and Hong Kong in the biopharmaceutical sector of GBA. We will fully leverage the synergistic advantages of both regions to establish an international clinical trial platform with the BAY TRIAL, continuously injecting new momentum into the high-quality development of the Bay Area’s pharmaceutical and medical device industry.”
Since the first discovery of AIDS in 1981, 40 million people have died from HIV infection. Currently, there are still over 39 million people living with HIV worldwide. Although antiretroviral therapy (“ART“) can effectively control HIV, it cannot cure the disease, highlighting the importance of immunotherapy. Immunotherapy aims to enhance the host’s immune response, with the expectation of controlling viral replication without ART, ultimately achieving complete viral suppression and functional cure. Immuno Cure’s ICVAX induces broad-spectrum, multifunctional virus-specific T cells to achieve the goal of controlling viral replication without ART.
Immuno Cure completed the first-in-human Phase I clinical trial of the ICVAX vaccine in November 2024. The results demonstrated excellent safety and good immunogenicity. This year, two multi-center Phase II clinical trials will be conducted to evaluate the mechanism of action and efficacy, respectively, of ICVAX in humans. Both are randomized, double-blind, placebo-controlled, dose-escalation studies, with clinical trial centres in the Prince of Wales Hospital in Hong Kong and eight Grade 3A hospitals in China, including The Third People’s Hospital of Shenzhen, Beijing Ditan Hospital, Beijing Youan Hospital, Guangzhou Eighth People’s Hospital, Tianjin Second People’s Hospital, The Sixth People’s Hospital of Zhengzhou, Chengdu Public Health Clinical Medical Center, and Chongqing Public Health Medical Center.
Dr. Xia JIN, Chief Executive Officer of Immuno Cure, said: “We are delighted to receive support from both GBAICTI and BAY TRIAL, integrating medical resources from both regions to advance Immuno Cure’s therapeutic vaccine for HIV, ICVAX, to multi-center Phase II clinical trials. We will continue to collaborate with the HKU AIDS Institute to drive innovation in drug development, leverage local advantages in drug research and translation, accelerate ICVAX towards commercialization, provide more effective treatment options for HIV patients, and contribute to global health.”
GBAICTI, BAY TRIAL, and Immuno Cure look forward to further deepening clinical trial cooperation between Shenzhen and Hong Kong in future collaborations, jointly promoting the development and globalisation of innovative drug development, and supporting the national “Healthy China” strategic goals.
Hashtag: #ImmunoCure #醫克生物 #医克生物
https://www.immunocure.hk/
https://www.linkedin.com/company/immuno-cure/
The issuer is solely responsible for the content of this announcement.
About GBAICTI
The Greater Bay Area International Clinical Trial Institute (GBAICTI) is located in the Hong Kong Park of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Co-operation Zone. Its mission is to coordinate public and private medical resources in Hong Kong, providing a one-stop support platform for research institutions. This aims to promote process optimization, talent training, and collaboration within the Greater Bay Area, accelerating the research and development of drugs and medical devices, allowing research outcomes to benefit patients more quickly. By closely collaborating with the Greater Bay Area International Clinical Trials Center, it leverages the unique advantages of “one institute, one center” to jointly coordinate cross-border, multi-center clinical trials that meet international standards.
To learn more about GBAICTI, please visit: https://gbaicti.hk/
About BAY TRIAL
The Greater Bay Area International Clinical Trials Center (BAY TRIAL) is a key initiative in implementing the “Notice of the State Council on Issuing the Development Plan for the Shenzhen Park of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone” (State Council [2023] No. 12). It serves as strong support for Shenzhen’s development as an international science and technology innovation centre and for promoting the high-quality development of the biopharmaceutical industry in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA). Located in the Hetao Shenzhen-Hong Kong Cooperation Zone, BAY TRIAL leverages the zone’s unique geographical and policy advantages to integrate clinical trial innovation resources across the GBA, deepen Shenzhen-Hong Kong science and technology collaboration, and establish a one-stop clinical trial platform. This platform provides top-tier clinical trial technical support, operational management, and registration services for domestic and international pharmaceutical and medical device R&D institutions. Additionally, BAY TRIAL will act as a “testing ground” for clinical trial regulation reforms and a “catalyst” for technological innovation, facilitating the alignment of clinical trial regulations and standards with international benchmarks, promoting the development and application of cutting-edge trial technologies, building a collaborative medical technology innovation network in the GBA, and enhancing the region’s competitiveness in the pharmaceutical and medical device industry.
To learn more about BAY TRIAL, please visit: https://baytrial.smart.org.cn/about/index.html
About Immuno Cure
Immuno Cure is a clinical stage biotechnology group based in the Hong Kong Science Park, focusing on research and development of innovative DNA medicines and antibody immunotherapies to fight against cancers, inflammatory and infectious diseases based on its patented PD-1-enhanced DNA Vaccine, Anti-Δ42PD1 Antibody; and Vaccine Delivery platforms.
To learn more about Immuno Cure, please visit: www.immunocure.hk
Acquisition creates a fully integrated regional connectivity platform, enabling seamless, low-latency connectivity that supports ASEAN’s expanding digital economy
SINGAPORE/KUALA LUMPUR, MALAYSIA – Media OutReach Newswire – 13 December 2025 – SEAX Global (“SEAX”), a leading wholesale connectivity provider in Southeast Asia, today announced it has acquired a major stake in Interlink Telecom Public Company Limited (“ITEL”), a prominent Thai fixed network telecommunications provider.
This acquisition consolidates SEAX’s presence across Malaysia, Singapore, Indonesia, and now Thailand, integrating ITEL’s nationwide fiber network infrastructure and telecommunications licences with SEAX’s regional subsea and terrestrial networks. By leveraging ITEL’s on-ground operational capabilities alongside SEAX’s cross-border reach, customers can expect faster deployment timelines, greater service flexibility, and more seamless regional connectivity.
ITEL Global, a new subsidiary formed to serve international requirements from both local and major global clientele, will continue managing operations within Thailand, preserving its local expertise and market familiarity while aligning with SEAX’s broader regional strategy to deliver a network footprint with unparalleled coverage, improved reliability, and a customer-centric approach throughout Southeast Asia.
Louis Teng, Group CEO of SEAX Global, said, “By bringing together our regional networks with ITEL’s deep local expertise in Thailand, we’re creating a powerful, customer-focused platform that can keep pace with the rapid digital transformation underway in ASEAN. This partnership enables us to deliver robust, low-latency connectivity solutions that meet the evolving needs of enterprises and digital ecosystems seeking seamless cross-border service.”
Dr. Nuttanai Anuntarumporn, Group CEO of Interlink Telecom, added, “Thailand’s digital infrastructure is evolving swiftly, and through collaboration with SEAX, we have the opportunity to become a regional seamless connectivity provider, developing and operating high-performance cross-border infrastructure connecting Thailand, Singapore, Malaysia, Indonesia, Vietnam, and Hong Kong. Together, we will jointly build and operate this infrastructure, integrate our networks, and deliver seamless regional connectivity across ASEAN.”
McKinsey highlights that Southeast Asia’s digital economy is projected to grow at a compound annual growth rate of nearly 20%, fuelled by rising digital adoption across businesses and consumers, and expanding digital services including cloud computing and online payments. This surge is driving robust demand for reliable fibre connectivity and cross-border data solutions critical for digital platforms, OTT providers, and multinational enterprises.
This strategic expansion creates an integrated end-to-end regional connectivity platform, improving network coverage, reliability, and service flexibility. SEAX’s SIJORI hub, covering Singapore, Johor Bahru, and Batam, complements Interlink’s Thailand network, critical as digital economy growth accelerates, especially via data centre and AI-related services.
Hashtag: #SEAXGlobal
The issuer is solely responsible for the content of this announcement.
SEAX Global
SEAX Global is a privately funded, geopolitically neutral leader in Southeast Asia’s wholesale connectivity solutions. Established in 2013, SEAX specializes in submarine and terrestrial cable systems, cable landing stations, and data center colocation, providing seamless, high-performance connectivity across the region.
SEAX is owned by Forbes Asia Billionaire Dato’ Dr. Low Tuck Kwong’s family, the Singapore-born Indonesian entrepreneur best known as the founder of Bayan Resources and one of Southeast Asia’s wealthiest businessmen.
The company holds full operational licenses in Malaysia, Singapore, and Indonesia. These licenses uniquely allow SEAX to build and operate private fixed networks for dedicated or enterprise use. Leveraging its regulatory compliance, extensive network portfolio, and regional expertise, SEAX empowers businesses with reliable, scalable, and secure data transmission, supporting cross-border connectivity and exceptional customer service across Southeast Asia while positioning itself for continued growth and regional expansion.
Interlink Telecom
Interlink Telecom Public Company Limited (ITEL) is Thailand Telecommunications Network Service Provider, with a type 3 Telecommunications License from The National Broadcasting and Telecommunications Commission (NBTC). ITEL provides telecommunication services through a fiber optic network nationwide in Thailand. The company offers various services, such as MPLS IP-VPN, dark fiber, wavelength, IPLC, as well as telecommunication network installation and broadcast services. ITEL also provides data center space services, including co-location, cloud computing, and disaster recovery services. ITEL was established in 2007 and headquartered in Bangkok, Thailand. In 2024–2025, ITEL expanded into its fourth business segment in medical equipment distribution and service. Through Interlink Health Technology (IHT), the company provides medical equipment rental services, supported by skilled technicians and mobile service units for hospitals nationwide.
Media OutReach
M7 World Championship unveils first Opening Ceremony, tournament draw, and M7 Pass—elevates Indonesia on global stage
The Swiss Stage sets up early mouthwatering clashes between tournament favourites—Team Liquid face Aurora Gaming PH in a Filipino showdown, while Selangor Red Giants face CG Esports in a Malaysian rivalry.
|
Region
|
Channels
|
|
MLBB Women’s Esports
|
|
|
Global
|
|
Hashtag: #MOONTONGames, #M7, #Esports, #Gaming
The issuer is solely responsible for the content of this announcement.
About MOONTON Games
Media OutReach
A First in the Asia-Pacific – Taiwan Leads the Launch of the Early Kidney Disease Annual Report, Opening a New Era in Advancing Kidney Care
- Yung-Ho Hsu, Secretary General of the Taiwan Society of Nephrology
- Shang-Jyh Hwang, Honorary President of the Taiwan Society of Nephrology
- Masaomi Nangaku, Immediate Past-President of the International Society of Nephrology
- Marcello Tonelli, President of the International Society of Nephrology
- Mai-Szu Wu, President of the Taiwan Society of Nephrology
- Chung-Liang Shih, Minister of the Ministry of Health and Welfare
- Ching-Fen Shen, Director General of the Health Promotion Administration, Ministry of Health and Welfare
- Chih-Cheng Hsu, Professor at the National Health Research Institutes
- Hyeong-Cheon Park, President Elect of the Asia Pacific Society of Nephrology
- Rajnish Mehrotra, President of the International Society of Peritoneal Dialysis
The complete and immediate analysis aids in reversing the past trend where most patients were diagnosed at late stages and required dialysis, ushering in a new era of early detection and treatment. Minister of Health and Welfare, Chung-Liang Shih, stated at a press conference that this annual report serves as a new engine for promoting precise care, integrating complete data and risk classification indicators for Early CKD P4P(Pay for Performance) and Pre-ESRD P4P. This fills the gap in early kidney disease data and strengthens the quantitative basis for policy and clinical decision-making, facilitating early intervention and delaying disease progression. The goal is to achieve the Healthy Taiwan Policy target of reducing the standardized mortality rate for chronic diseases by one-third by 2030, and for Taiwan’s care model to become an example in the Asia-Pacific, establishing a sustainable and precise new framework for kidney care.
The early kidney disease annual report reveals several key trends. According to KDIGO risk classification, the proportion of high-risk and very high-risk patients in the P4P program has gradually decreased in recent years, reflecting a shift in treatment strategies toward early intervention and prevention. This trend not only highlights the medical team’s emphasis on the care of early-stage chronic kidney disease patients but also helps delay disease progression and reduce the incidence of later-stage complications. In terms of controlling the “three highs” (hyperglycemia, hypertension, and hyperlipidemia), data shows that approximately 80% of patients meet lipid targets and nearly 60% maintain stable blood sugar levels. However, only about 30% meet the target for blood pressure below 130/80 mmHg, indicating significant challenges remain in blood pressure control. The “three highs” are important risk factors for the progression and deterioration of chronic kidney disease, making it crucial to further improve control rates. The implementation of the P4P program has already shown preliminary results, and there are expectations for more immediate, comprehensive, and rigorous data collection and tracking, which will more fully demonstrate the long-term benefits of this care model.
Data-Driven: Taiwan’s First Early Kidney Disease Annual Report Fills Care Gaps
Professor Chih-Cheng Hsu from the National Health Research Institutes pointed out that past domestic kidney disease care has primarily focused on dialysis and end-stage disease, with limited understanding of early stages and delayed updates on data. This annual report breaks through traditional reporting frameworks and represents the first integration of complete data and risk classification indicators for Early CKD P4P and Pre-ESRD P4P. Utilizing big data for in-depth analysis, it outlines the disease progression and comorbidity trends of patients at different risk levels, successfully filling the long-term gap in early kidney disease care. He noted that grasping information on early stages of disease helps clinicians intervene earlier and delay deterioration while providing quantitative evidence for health policies to promote proactive and timely kidney care strategies, enhancing Taiwan’s international competitiveness in precise health governance.
Early CKD P4P and Pre-ESRD P4P are two phased quality-based reimbursement programs promoted by the National Health Insurance Administration, addressing key care needs for early chronic kidney disease and pre-dialysis patients, respectively. Early CKD P4P primarily targets patients in CKD stages 1-3a, aiding healthcare institutions in early identification of kidney deterioration risks through disease tracking and integrated care models, providing personalized management. Pre-ESRD P4P focuses on patients in CKD stages 3b, 4-5, enhancing control of complications, medication, and nutritional management while utilizing data feedback to support treatment decisions, aiming to delay dialysis and improve care efficiency. Both programs link the complete processes from early prevention to pre-dialysis intervention, contributing to improved overall CKD care quality and patient long-term prognosis.
Precise Kidney Care: Holistic and Continuous CKD Care as a Model for Chronic Disease
Taiwan centers its approach on “precise care,” continuously optimizing the integrated chronic kidney disease care system to implement policy blueprints in clinical practice. Director General of National Health Insurance Administration, Lian-Yu Chen, mentioned that Taiwan has progressively refined various measures, from educational programs for pre-end-stage renal disease patients to integrated care plans for early chronic kidney disease. The medical team can adjust personalized treatment strategies based on patient risk classification and clinical data, strengthening disease management and follow-up effectiveness for early-stage patients. She indicated that by integrating and providing feedback across units, care gaps could be minimized to ensure that patients receive consistent medical services across different levels of care. Director General of Health Promotion Administration, Ching-Fen Shen, remarked that grassroots health education and community health advocacy go hand in hand to enhance public awareness of kidney health. Years of efforts have significantly slowed the deterioration of early kidney disease progression, with patients participating in integrated care exhibiting a lower future risk of dialysis compared to those who do not participate, showing tangible effectiveness of the Taiwan model.
Policy Linkage and Sustainable Vision: Achieving the Healthy Taiwan Goals and Leading the New Landscape of Asia-Pacific
In response to the government’s “Healthy Taiwan” policy, Taiwan is implementing a preventive kidney care model based on the Early CKD P4P and Pre-ESRD P4P systems and the Early Kidney Disease Annual Report. President of the Taiwan Society of Nephrology, Mai-Szu Wu, stated that investing in early chronic kidney disease management not only contributes to health sustainability but also reduces waste of medical resources, achieving dual benefits of health outcomes and environmental sustainability, assisting the government in its goal to reduce chronic disease mortality by one-third by 2030.
During the Asia-Pacific Nephrology Conference (APCN) held in Taipei this year, the Asia-Pacific’s first Early Kidney Disease Annual Report was officially unveiled. President of the International Society of Nephrology, Marcello Tonelli, and Immediate Past-President , Masaomi Nangaku, along with the President Elect of the Asia Pacific Society of Nephrology Hyeong-Cheon Park and Honorary Secretary Sunita Bavanandan attended as witnesses, attracting experts from South Korea, Japan, Thailand, Malaysia, Australia, New Zealand, Singapore, Hong Kong, Mongolia, Indonesia, and the Philippines. Additionally, various important domestic academic societies, including the Taiwan Academy of Family Medicine, Taiwan Society of Cardiology, the Diabetes Association of the Republic of China (Taiwan), the Taiwan Association of Clinical Diabetes, and the Taiwan Medical Clinics Association also participated and supported the event. Minister Chung-Liang Shih expressed gratitude for the collective efforts and emphasized that this kidney annual report showcases Taiwan’s leading position in medical data integration and clinical evidence, hoping that real-time and comprehensive data analysis will once again showcase Taiwan’s precision care model to the international community, working together with other countries to create a new global framework for chronic kidney disease prevention and treatment.
Hashtag: #TaiwanSocietyofNephrology
The issuer is solely responsible for the content of this announcement.
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism9 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking7 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn